Do You Need Antiviral Treatment for COVID-19? Here's What Current Guidance Says
If you've recently tested positive for COVID-19 and aren't sure whether you should be taking an antiviral medication, you're not alone. With a lot of information floating around online, it can be hard to know what actually applies to you. The good news: Expert guidelines make it clear who benefits most from treatment—and who can safely skip it.
Here's what you need to know.
It depends on your risk
Not everyone who gets COVID-19 needs antiviral treatment. Thanks to widespread vaccination and high rates of prior infection, the risk of severe illness is much lower than it used to be for many people. But for those who are at higher risk of ending up in the hospital, antivirals can make a real difference.
That's why current guidelines from the Infectious Diseases Society of America (IDSA) use a risk-based approach: the higher your risk of severe illness, the stronger the case for treatment.
So, who should get treated?
The IDSA groups patients into three categories based on their likelihood of progressing to severe COVID-19. Here's how it works:
High risk: Treatment is strongly recommended
You're considered high risk if you have any of the following:
- Age 75 or older
- A solid organ transplant (such as kidney, liver, or heart)
- A stem cell transplant within the past 2 years
- A blood cancer (like leukemia or lymphoma) that's currently being treated
- HIV with a CD4 count below 200
- A solid tumor being treated with immunosuppressive therapy
- A severe primary immunodeficiency
- Graft-versus-host disease
- Very low B-cell counts (less than 1% of peripheral blood cells)
- Current use of certain medications that significantly weaken the immune system
If you fall into this group, the evidence is strong: Antiviral treatment can prevent roughly 50 out of every 1,000 high-risk patients from being hospitalized.
Increased risk (but not high risk): Treatment is worth discussing with your provider
You may fall into this middle category if you have one or more of the following:
- Age 65–74
- Diabetes
- Obesity
- Heart disease, heart failure, or cardiomyopathy
- Chronic lung disease or asthma
- Chronic liver disease or cirrhosis
- Chronic kidney disease or end-stage kidney disease
- Conditions that affect blood flow to the brain (cerebrovascular disease)
- Dementia
- Current pregnancy or within 6 weeks of delivery
- A history of smoking
- Physical inactivity
- Down syndrome or other disabilities
- Certain mental health conditions
- Inflammatory bowel disease
- Parkinson's disease
- HIV with a CD4 count above 200
- Tuberculosis
- Certain medications that have a mild effect on the immune system
For this group, treatment is a reasonable option, but the decision should be a conversation between you and your provider. Your individual circumstances, other medications, and personal preferences all factor in.
No risk factors: Treatment is generally not recommended
If you're a younger, otherwise healthy person without any of the conditions listed above, the expected benefit of antiviral treatment is very small—roughly 4 fewer hospitalizations per 1,000 people. For most people in this group, the potential downsides (side effects, drug interactions, cost) outweigh the modest benefit.
What are the treatment options?
There are three FDA-authorized antiviral medications for mild to moderate COVID-19. Your provider will help determine which one is right for you based on your risk level, other medications, and practical considerations.
Paxlovid (nirmatrelvir/ritonavir): The first-line option for most people
Paxlovid is an oral medication that’s taken twice daily for 5 days. It must be started within 5 days of your first symptoms. Paxlovid was first tested in people who were unvaccinated and at high risk for severe COVID-19, and it lowered their chance of being hospitalized or dying by about 85–90%. Now that most people have some immunity from vaccines or past COVID-19 infection, fewer people get very sick in the first place, so the benefit is smaller. A 2025 study found that Paxlovid prevented about 1 hospitalization for every 100 people treated, and a 2026 clinical trial in mostly vaccinated higher-risk adults found no clear reduction in hospital stays, though people tended to feel better sooner. Paxlovid still makes the most sense for people at the highest risk, such as adults 65 and older or people with weakened immune systems. Most people tolerate Paxlovid well, but it may cause a metallic or altered taste while taking it, and some people experience stomach upset. An important caveat is that Paxlovid interacts with many common medications, including certain heart medications, blood thinners, and cholesterol drugs, among others. Your provider will need to review your full medication list before prescribing. In many cases, interactions can be managed by temporarily pausing or adjusting other medications.
Remdesivir (Veklury): An IV alternative
Remdesivir is given as an intravenous (IV) infusion over 3 consecutive days. It must be started within 7 days of your first symptoms. Remdesivir is the most effective alternative for high-risk patients who can't take Paxlovid due to drug interactions or for other reasons, but availability is very limited, and the logistics can be complicated even in locations where remdesivir is available.
Molnupiravir (Lagevrio): A last-resort option
Like Paxlovid, molnupiravir is an oral medication taken twice daily for 5 days. While molnupiravir has fewer drug interactions than Paxlovid and is more convenient than remdesivir, it’s only recommended for high-risk patients when neither Paxlovid nor remdesivir is available or appropriate. Recent studies show that molnupiravir has little effect on the risk of hospitalization or death, and it’s therefore mainly a backup option for people who can't take Paxlovid.
Importantly, molnupiravir is not recommended for children under the age of 18 or people who are breastfeeding, pregnant, or trying to get pregnant. People who could become pregnant should use a reliable method of birth control during treatment with molnupiravir and for 4 days after the last dose. People assigned male at birth who are sexually active with a partner who could become pregnant should use a reliable method of birth control during treatment and for at least 3 months after the last dose of molnupiravir.
What about "Paxlovid rebound"?
You may have heard about people whose symptoms return after finishing Paxlovid. This does happen in a small percentage of cases (roughly 1–7%), but it's important to know that symptom rebound also occurs in people who take molnupiravir or don't take any antiviral at all. When rebound does happen, it's generally mild and doesn’t need additional treatment with antiviral medication.
The bottom line
Here's what to remember:
- Not everyone with COVID-19 needs antiviral treatment. The benefit depends on your personal risk of severe illness.
- If you're at high risk—especially if you are age 75 or older or have a weakened immune system—antiviral treatment is recommended and may reduce your chance of hospitalization.
- If you have some risk factors, talk to your provider. Together, you can weigh the benefits against any potential downsides like drug interactions or side effects.
- Timing matters. Antivirals work best when started early—within 5 days of symptoms for Paxlovid and molnupiravir, and within 7 days for remdesivir. If you think you might have COVID-19 and might benefit from treatment, reach out to your provider right away.
- Your provider is your best resource. Every person's situation is different, and your One Medical care team can help you make the decision that's right for you.
Have questions about COVID-19 treatment? Book a virtual visit with your One Medical provider or use On-Demand Care 24/7 to discuss your options.
The One Medical blog is published by One Medical, a national, modern primary care practice pairing 24/7 virtual care services with inviting and convenient in-person care at over 100 locations across the U.S. One Medical is on a mission to transform health care for all through a human-centered, technology-powered approach to caring for people at every stage of life.
Any general advice posted on our blog, website, or app is for informational purposes only and is not intended to replace or substitute for any medical or other advice. 1Life Healthcare, Inc. and the One Medical entities make no representations or warranties and expressly disclaim any and all liability concerning any treatment, action by, or effect on any person following the general information offered or provided within or through the blog, website, or app. If you have specific concerns or a situation arises in which you require medical advice, you should consult with an appropriately trained and qualified medical services provider.